The annual payout for Herceptin in the UK alone has been put at £100m, i.e., about a quarter of the total cancer drug bill for the whole NHS.
In June, drug industry experts estimated global sales of Herceptin “will nearly triple” within the decade to $3.3 billion (21 June 2006 Decision Resources, Inc press release).
Tony Edwards